{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-298052","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.894918+00:00","generated_at":"2026-06-21T09:31:10.320051+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Karyopharm raises $165M in PIPE; sells 31.8M shares at $5.19 with warrants","bullets":["Gross proceeds ~$165M from sale of 31,791,908 shares at $5.19 and warrants for 9,537,563 shares at $6.36.","Lead investors include Avidity Partners, Adage Capital, Armistice Capital, and others; expected close Dec 7, 2022.","Proceeds to fund selinexor and eltanexor clinical programs, working capital; cash runway extended into late 2025.","Warrants exercisable for five years after closing; registration statement for resale to be filed within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-298052","json":"https://secwatch.observer/filing/0001193125-22-298052.json","markdown":"https://secwatch.observer/filing/0001193125-22-298052.md","text":"https://secwatch.observer/filing/0001193125-22-298052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522298052/0001193125-22-298052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522298052/d418804d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:31:10.320051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30113288b3e8b43378d0ac638286ccfa13d929da","claim":"Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $165 million (effective 2022-12-05).","evidence_excerpt":"On December 5, 2022, Karyopharm Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement an aggregate of (i) 31,791,908 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and (ii) accompanying warrants (the “ Warrants ”) to purchase up to 9,537,563 shares of Common Stock (collectively, the “ Private Placement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522298052/0001193125-22-298052-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $165 million"},{"label":"Effective","value":"2022-12-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}